POSC31 Comparison of Atezolizumab, Nivolumab, and Pembrolizumab in Elderly Cancer Patients over 65 Years of Age
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.177
https://www.valueinhealthjournal.com/article/S1098-3015(21)01972-0/fulltext
Section Title :
Section Order :
10944
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01972-0&doi=10.1016/j.jval.2021.11.177